Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Income (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Operating Income for 13 consecutive years, with -$59.6 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 11.03% to -$59.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$300.1 million through Dec 2025, up 39.72% year-over-year, with the annual reading at -$300.1 million for FY2025, 39.72% up from the prior year.
  • Operating Income for Q4 2025 was -$59.6 million at Madrigal Pharmaceuticals, up from -$114.0 million in the prior quarter.
  • The five-year high for Operating Income was -$47.2 million in Q2 2025, with the low at -$162.5 million in Q2 2024.
  • Average Operating Income over 5 years is -$85.7 million, with a median of -$78.8 million recorded in 2023.
  • The sharpest move saw Operating Income tumbled 94.08% in 2024, then soared 70.96% in 2025.
  • Over 5 years, Operating Income stood at -$64.6 million in 2021, then tumbled by 32.04% to -$85.3 million in 2022, then plummeted by 37.37% to -$117.2 million in 2023, then skyrocketed by 42.82% to -$67.0 million in 2024, then increased by 11.03% to -$59.6 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$59.6 million, -$114.0 million, and -$47.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.